奥拉西坦联合依达拉奉治疗急性脑梗死的临床观察  

Clinical Observation of Oxiracetam Combined with Edaravone in the Treatment of Acute Cerebral Infarction

作　　者：刘家斌[1] 王明琪[1] 欧阳懿[1] LIU Jia-bin;WANG Ming-qi;OU Yang-yi(Ganzhou, Jiangxi People's Hospital, Department of Neurology, Ganzhou Jiangxin 341000, China)

机构地区：[1]江西省赣州市人民医院神经内科,江西赣州341000

出　　处：《药品评价》2016年第22期43-44,47,共3页Drug Evaluation

摘　　要：目的:探讨奥拉西坦联合依达拉奉治疗急性脑梗死的临床疗效。方法:将2015年2月—2016年2月于我院就诊且确诊为急性脑梗死的83例患者纳入研究并分组,对照组42例,观察组41例。两组患者依据《中国脑血管病防治指南》行常规治疗,予他汀类调脂,甘露醇降低颅内压,尿激酶溶栓等常规治疗,对照组加用奥拉西坦治疗,观察组则加用奥拉西坦、依达拉奉,比较两组日常生活能力(Barthel评分)、神经功能缺损(NIHSS评分)改善情况及疗效差异。结果:两组患者Barthel评分升高,NIHSS降低,但观察组改善更显著,P<0.05;观察组基本治愈例数更多,且总有效率更高,P<0.05。结论:奥拉西坦联合依达拉奉治疗效果显著,可缩短病程,促进神经功能恢复。Objective: To investigate clinical efficacy of Oxiracetam edaravone in the treatment of acute cerebral infarction. Methods: 83 patientsdiagnosed with acute cerebral infarction from February 2015 to February 2016 in our hospital were divided into two groups: control group (42cases), and observation group (41 cases). Two groups of patients underwent conventional treatment based on "China Cerebrovascular DiseasePrevention Guide", used statins, mannitol to reduce intracranial pressure, and other conventional thrombolytic therapy. In addition, the controlgroup was treated with oxiracetam, the observation group plus oxiracetam edaravone, daily living (Barthel score), neurological deficits (NIHSSscore)improvement and difference in efficacy between two groups were compared. Results: Barthel score was elevated, NIHSS decreased in twogroups, and the observation group improved more significantly, P<0.05; observation group cured more cases, P<0.05. Conclusion: Oxiracetamedaravone significant improve treatment effect, shorten the course, promote the recovery of neurological function.

关 键 词：奥拉西坦 依达拉奉 急性脑梗死 临床观察 

分 类 号：R743.33[医药卫生—神经病学与精神病学]